Genmab — November 2025
-
Fitch Ratings on Monday assigned an expected first-time long-term issuer default rating of BB to Genmab https://www.fitchratings.com/research/corporate-finance/fitch-rates-genmab-a-s-bb-exp-outlook-stable-10-11-2025
-
S&P - Danish Pharmaceutical Company Genmab A/S Assigned 'BB+' Rating; Outlook Stable https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3475716
-
Moody's Ratings assigns Ba2 rating to Genmab, outlook stable https://ratings.moodys.com/ratings-news/454170
-
Samtidig forventes nyhedsflowet for resten af 2025 og begyndelsen af 2026 at blive mere afdæmpet, hvor resten af 2025 byder på: 1) Potentiel godkendelse af Epkinly i FL, hvor FDA har sat godkendelsesdatoen til 30. november 2025. Genmab ser ingen årsager til, at produktet ikke skulle blive godkendt.
-
- Opfølgende fase 2-data på acasunilimab i NSCLC, som bliver præsenteret på ESMO den 10.–12. december. Ser vi frem mod 2026, begynder året roligt, mens andet halvår byder på fase 3-data for Epkinly + R-CHOP i 1L DLBCL (EPCORE DLBCL-2) og data i 2L DLBCL (EPCORE DLBCL-1) samt fase 3-data for RINA-S i RAINFALL-02-studiet.
-
i am a bit troubled by the fact that they still show a P/E of 124 in their analysis, they still have mistakes in their spreadsheet, probably mixing $ and DKK... via the pdf here
https://www.jyskebank.dk/finansnyt/aktier/publikation/oktober-2025 -
https://clinicaltrials.gov/study/NCT07226752 new trial in China, while Chinese centers in EPCORE DLBCL-1 are removed, looks like they want to separate the Chinese part
https://clinicaltrials.gov/study/NCT04628494?tab=history&a=49&b=50&compareMode=sideBySide#version-content-panel -
https://pj.jiho.jp/article/254090 anssen Pharmaceutical (J&J) said on October 31 that it has filed the combination of its bispecific antibodies Talvey (talquetamab) and Tecvayli (teclistamab) in rMM - i don't think they have filed this with the FDA already?
-
Reduced Risk of Cardiovascular Disease Observed With Teprotumumab vs Corticosteroids https://www.aao.org/education/editors-choice/reduced-risk-of-cardiovascular-disease-observed-wi
-
BioNTech Innovation Series R&D Day 2025 https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2025/11/11/13-27-51/BNTX Innovation Series (R%26D) Day 2025_final_ website.pdf mostly for BNT314 /GEN1059 , GEN1042 still in the pipeline
-
Genmab pushes rina-S into its third phase 3
13 November 2025 https://www.oncologypipeline.com/apexonco/genmab-pushes-rina-s-its-third-phase-3 -
Epcoritamab for Relapsed/Refractory EBV+ Post-Transplant Lymphoproliferative Disorder of DLBCL-Type https://onlinelibrary.wiley.com/doi/10.1002/jha2.70156
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind